Biotech Values

[apljack]

NGNM (and RGDX):

Peter, thanks for the input. It's always good to hear from someone more knowledgeable regarding the technical aspects of news than myself.

With regard to RGDX (which, BTW, had been involved in potential partnering talks with NGNM in the past), the news is that GSK has taken a considerable position in the co., not unlike ABT's move to take a position in NGNM about 18 months ago. Read the following:

BRIEF-GlaxoSmithKline acquires shares in Response Genetics

http://www.reuters.com/article/2012/09/13/glaxosmithkline-brief-idUSWLA324120120913?type=companyNews&feedType=RSS&feedName=companyNews&rpc=43

"(Reuters) - GlaxoSmithKline Plc : * GSK acquires shares in Response Genetics Inc * Acquired five million newly issued shares of Response Genetics Inc * To acquire the shares in Response Genetics for US$1.10 per share in cash * As a result, GSK now owns approximately 15.2% of the expanded share capital"

Best,

AJ